Beyond "Simple Models": A New Transformation in Drug R&D | BlueRun Ventures Bio-Tech Salon · Bio2X

Traditional drug development inevitably faces challenges: long cycles, high costs, low success rates, and the fact that most targets remain difficult to drug. How to apply cutting-edge technologies like AI, automation, and live-cell screening to pharmaceutical R&D has long been an area of innovation the industry has been exploring.

This Saturday, June 25, from 10:00 to 12:00, BlueRun Ventures will host an online biotech salon titled "Beyond 'Simple Models': A New Transformation in Drug R&D," featuring DeepWise, Xinyue Biotech, Ketu Medicine, and Leadart Therapeutics. The discussion will center on AI for Science, live-cell drug screening, phenotypic screening, chemoproteomics, and other frontier technologies driving innovation in drug development models.

Topics we'll cover include:

• What bottlenecks have traditional "reductionist models" hit in drug research?
• How can new drug development paradigms break through the challenges of "difficult-to-drug" and "undruggable" targets?
• How can AI integrate with frontier biotech to create new drug development models?
• Pipeline vs. Platform — how should early-stage biotech startups choose their business model?
• ...

This event will be held via Tencent Meeting. Founders, industry professionals, academic researchers, and investors are all welcome to scan the QR code to join! To ensure meaningful online engagement, this event will use a pre-registration system. Please scan the code to fill out the registration form and submit topics or questions you'd like to discuss with our guests — we'll address them during the session.

See you online!

BlueRun Ventures was founded in 1998 in Silicon Valley. BlueRun Ventures China was established in 2005 as a venture capital firm focused on early-stage startups.

Today, BlueRun Ventures China manages multiple USD and RMB dual-currency funds with over RMB 15 billion in assets under management, making it one of the largest early-stage funds in the country. The firm invests primarily at Pre-A and Series A stages across hard tech and innovative interaction, enterprise technology, new consumer, and healthcare sectors. It has backed more than 150 startups, including Li Auto, Waterdrop, QingCloud, Guazi.com, Qudian, Songguo Mobility, Ganji.com, Energy Monster, Yuntu Semiconductor, Machenike, CloudSaint Intelligence, Anxin Network Shield, and BioMap.

BlueRun Ventures has been ranked #1 on Zero2IPO's "China Top 30 Early-Stage Investment Institutions" and ChinaVenture's "China Best Early-Stage Venture Capital Firms TOP30," and was named among Preqin's Top 10 VC fund managers globally for consistent high returns.

The firm has also received consecutive recognition from Forbes China, 36Kr, Cyzone, Caixin Media, CBNweekly, Jiemian, and other media as "China's Best Early-Stage Firm of the Year," "China Top-Tier Venture Capital Firm," "Most Founder-Friendly Early-Stage Firm of the Year," and "Most Influential Early-Stage Firm of the Year."